167 related articles for article (PubMed ID: 38714690)
1. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.
Maura F; Coffey DG; Stein CK; Braggio E; Ziccheddu B; Sharik ME; Du MT; Tafoya Alvarado Y; Shi CX; Zhu YX; Meermeier EW; Morgan GJ; Landgren O; Bergsagel PL; Chesi M
Nat Commun; 2024 May; 15(1):3844. PubMed ID: 38714690
[TBL] [Abstract][Full Text] [Related]
2. The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity.
Maura F; Coffey DG; Stein CK; Braggio E; Ziccheddu B; Sharik ME; Du M; Alvarado YT; Shi CX; Zhu YX; Meermeier EW; Morgan GJ; Landgren O; Leif Bergsagel P; Chesi M
bioRxiv; 2023 Jul; ():. PubMed ID: 37546905
[TBL] [Abstract][Full Text] [Related]
3. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
Chesi M; Robbiani DF; Sebag M; Chng WJ; Affer M; Tiedemann R; Valdez R; Palmer SE; Haas SS; Stewart AK; Fonseca R; Kremer R; Cattoretti G; Bergsagel PL
Cancer Cell; 2008 Feb; 13(2):167-80. PubMed ID: 18242516
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
McFadden DG; Politi K; Bhutkar A; Chen FK; Song X; Pirun M; Santiago PM; Kim-Kiselak C; Platt JT; Lee E; Hodges E; Rosebrock AP; Bronson RT; Socci ND; Hannon GJ; Jacks T; Varmus H
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6409-E6417. PubMed ID: 27702896
[TBL] [Abstract][Full Text] [Related]
5. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.
David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N
Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
Chng WJ; Huang GF; Chung TH; Ng SB; Gonzalez-Paz N; Troska-Price T; Mulligan G; Chesi M; Bergsagel PL; Fonseca R
Leukemia; 2011 Jun; 25(6):1026-35. PubMed ID: 21468039
[TBL] [Abstract][Full Text] [Related]
7. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
8. GP130 activation induces myeloma and collaborates with MYC.
Dechow T; Steidle S; Götze KS; Rudelius M; Behnke K; Pechloff K; Kratzat S; Bullinger L; Fend F; Soberon V; Mitova N; Li Z; Thaler M; Bauer J; Pietschmann E; Albers C; Grundler R; Schmidt-Supprian M; Ruland J; Peschel C; Duyster J; Rose-John S; Bassermann F; Keller U
J Clin Invest; 2014 Dec; 124(12):5263-74. PubMed ID: 25384216
[TBL] [Abstract][Full Text] [Related]
9. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
[No Abstract] [Full Text] [Related]
10. Clonal competition with alternating dominance in multiple myeloma.
Keats JJ; Chesi M; Egan JB; Garbitt VM; Palmer SE; Braggio E; Van Wier S; Blackburn PR; Baker AS; Dispenzieri A; Kumar S; Rajkumar SV; Carpten JD; Barrett M; Fonseca R; Stewart AK; Bergsagel PL
Blood; 2012 Aug; 120(5):1067-76. PubMed ID: 22498740
[TBL] [Abstract][Full Text] [Related]
11. Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.
Wang L; Deng Q; Hu H; Liu M; Gong Z; Zhang S; Xu-Monette ZY; Lu Z; Young KH; Ma X; Li Y
J Hematol Oncol; 2019 Jul; 12(1):70. PubMed ID: 31277689
[TBL] [Abstract][Full Text] [Related]
12. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
13. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH
Nat Commun; 2019 Apr; 10(1):1911. PubMed ID: 31015454
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
16. Role of the translocation partner in protection against AID-dependent chromosomal translocations.
Jankovic M; Robbiani DF; Dorsett Y; Eisenreich T; Xu Y; Tarakhovsky A; Nussenzweig A; Nussenzweig MC
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):187-92. PubMed ID: 19966290
[TBL] [Abstract][Full Text] [Related]
17. Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M; Bergsagel PL
Int J Lab Hematol; 2015 May; 37 Suppl 1():108-14. PubMed ID: 25976968
[TBL] [Abstract][Full Text] [Related]
18. Modeling multiple myeloma by AID-dependent conditional activation of MYC.
Kuehl WM
Cancer Cell; 2008 Feb; 13(2):85-7. PubMed ID: 18242508
[TBL] [Abstract][Full Text] [Related]
19. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
Calado DP; Sasaki Y; Godinho SA; Pellerin A; Köchert K; Sleckman BP; de Alborán IM; Janz M; Rodig S; Rajewsky K
Nat Immunol; 2012 Nov; 13(11):1092-100. PubMed ID: 23001146
[TBL] [Abstract][Full Text] [Related]
20. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
